Introduction
============

Prostate cancer (PCa) remains the cancer with the highest incidence and third highest cause of cancer-associated mortality in males, with an estimated 161,360 new cases and 26,730 mortalities, according to 2017 statistics ([@b1-mmr-18-06-5630]). A number of factors contribute to the survival of patients with PCa, particularly the disease stage at the time of diagnosis. Therefore, the early detection of PCa may improve clinical treatment and patient prognosis. Various techniques for the diagnosis of PCa have been developed; these include pathological biopsy, the gold standard in diagnosis, and other detection methods, including the prostate-specific antigen (PSA) assay ([@b2-mmr-18-06-5630]--[@b4-mmr-18-06-5630]), positron emission tomography ([@b5-mmr-18-06-5630]), multiparametric magnetic resonance imaging ([@b6-mmr-18-06-5630],[@b7-mmr-18-06-5630]), and urinary long non-coding RNA and microRNA (miRNA/miR) detection ([@b8-mmr-18-06-5630],[@b9-mmr-18-06-5630]), which have also been used in clinical diagnosis. Despite progress, PCa still requires further novel diagnostic biomarkers to aid in its diagnosis.

miRNAs are known to have a crucial role in the regulation of tumor suppressor genes and oncogenes, resulting in the regulation of cell proliferation and apoptosis ([@b10-mmr-18-06-5630]). miR-1 has been previously reported to be implicated in various tumors ([@b11-mmr-18-06-5630]). The diagnostic value of miR-1 has been reported in breast cancer ([@b12-mmr-18-06-5630]), colorectal cancer ([@b13-mmr-18-06-5630]) and prostate recurrence ([@b14-mmr-18-06-5630]). Details of the molecular mechanisms of miR-1 in diverse cancer types have been reported over the years. For example, the HOX transcript antisense RNA-miR-1-cyclin D2 axis was reported to promote thyroid cancer cell growth, invasion and migration ([@b15-mmr-18-06-5630]). miR-1 was revealed to suppress colorectal cancer cell proliferation by inhibiting SMAD3-mediated tumor glycolysis ([@b16-mmr-18-06-5630]). In bladder cancer, miR-1 suppressed cell proliferation, invasion and migration by upregulating secreted frizzled-related protein 1 expression ([@b17-mmr-18-06-5630]). miR-1 was also reported to inhibit breast cancer progression by downregulating K-ras and metastasis associated lung adenocarcinoma transcript 1 ([@b18-mmr-18-06-5630]). Regarding PCa, Chang *et al* ([@b19-mmr-18-06-5630]) identified that the epidermal growth factor receptor was able to boost PCa bone metastasis by downregulating miR-1 and activating twist-related protein 1 (TWIST1). Stope *et al* ([@b20-mmr-18-06-5630]) reported that heat-shock protein β-1 reduced the expression of miR-1, which restored oncogenic pathways in PCa cells.

Despite all the studies regarding miR-1 in PCa, to the best of our knowledge, no study has examined its clinical diagnostic significance via systematic meta-analysis and identified the potential target genes and pathways using bioinformatics methods. Therefore, it was necessary for the present study to conduct systematic meta-analysis and bioinformatics analysis to comprehensively evaluate the diagnostic value of miR-1, and examine the potential molecular modulatory mechanisms in PCa. The aim of the present study was to elucidate the diagnostic value of miR-1 in PCa in a more comprehensive way and pose a perspective into the potential molecular mechanism, which may contribute to clinical diagnosis and treatment.

In the present study, a meta-analysis using Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), ArrayExpress and data from published literature was conducted, to assess the clinical diagnostic value of miR-1 in PCa. By collecting the potential target genes of miR-1 and using bioinformatics analysis, the important targets and signaling pathways of miR-1 in PCa were identified. The present study may aid validation of the diagnostic value of miR-1 in PCa and provide insight into the theoretical molecular modulatory mechanisms for future studies.

Materials and methods
=====================

### Collection of miR-1 expression data from TCGA

miRNA expression matrix was downloaded from TCGA (<https://cancergenome.nih.gov/>) ([@b21-mmr-18-06-5630]). The expression data of miR-1-1 and miR-1-2 were included in the investigation. Samples missing miR-1-1 or miR-1-2 expression data were removed from the present research. All the data was normalized using log2 conversion. Additionally, mRNA data was downloaded from the portal of prostate adenocarcinoma in TCGA. The DESeq package ([@b22-mmr-18-06-5630]) in the R program (version 3.30) was applied to obtain the differentially expressed genes (DEGs).

### Retrieval of GEO and ArrayExpress PCa datasets

To analyze the expression level of miR-1 in PCa and non-tumor tissue, the GEO and ArrayExpress databases were searched. The key words were as follows: Prostat\* and (malignan\* OR cancer OR tumor OR tumour OR tumor OR neoplas\* OR carcinoma). Microarray datasets that contained the miR-1 values were included. All the data in the datasets were calculated in the log2 scale for normalization. To collect DEGs in PCa following miR-1 pretreatment, the Gene Expression Omnibus (GEO) and ArrayExpress databases were additionally searched with the following retrieval strategies: Prostat\* and (malignan\* OR cancer OR tumor OR tumor OR neoplas\* OR carcinoma) and (miR-1 OR miRNA-1 OR microRNA-1 OR miR1 OR miRNA1 OR microRNA1 OR 'miR 1' OR 'miRNA 1' OR 'microRNA 1' OR miR-1-3p OR miRNA-1-3p OR microRNA-1-3p OR miR-1-1 OR miR-1-2 OR miR1-1 OR miR1-2). Microarrays containing mRNA expression following miR-1 silencing or overexpression were enrolled for further analysis.

### Retrieval of published literatures

PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), Science Direct (<https://www.sciencedirect.com/>), Google Scholar (<https://scholar.google.com/>), Ovid (<http://www.ovid.com>), Wiley Online Library (<https://onlinelibrary.wiley.com/>), EMBASE (<https://www.embase.com>), Web of Science (<https://clarivate.com/products/web-of-science/>), Chong Qing VIP (<http://qikan.cqvip.com/>), CNKI (<http://cnki.net/>), Wan Fang ([www.wanfangdata.com.cn](www.wanfangdata.com.cn)) and China Biology Medicine Disc (<http://www.sinomed.ac.cn/>) were used for literature retrieval. The searching strategies were as follows: Prostat\* and (malignan\* OR cancer OR tumor OR tumor OR neoplas\* OR carcinoma) and (miR-1 OR miRNA-1 OR microRNA-1 OR miR1 OR miRNA1 OR microRNA1 OR 'miR 1' OR 'miRNA 1' OR 'microRNA 1' OR miR-1-3p OR miRNA-1-3p OR microRNA-1-3p OR miR-1-1 OR miR-1-2 OR miR1-1 OR miR1-2). Studies for which the mean, standard deviation and case number of miR-1 in prostate cancer and non-tumor groups were available were further analyzed. Additionally, studies that provided the true positive, false positive, false negative and true negative values were included in the diagnostic meta-analysis.

### Identification of putative miR-1 target genes

For the microarray data with silenced or overexpressed miR-1, the mRNA expression was analyzed and log2 fold change (FC) was calculated to select the DEGs. Log~2~FC\<0 or log~2~FC\>0 was adopted to screen the downregulated or upregulated genes in the miR-1 overexpressed or silenced microarrays, respectively. Additionally, DEGs were obtained from the TCGA data through the standard log~2~FC\>1. Furthermore, the miRWalk 2.0 tool (<http://zmf.umm.uni-heidelberg.de/mirwalk2/>) ([@b23-mmr-18-06-5630]), which links to 11 other online prediction databases, was used to predict the putative target genes of miR-1. Targets predicted by more than two datasets were finally selected. Genes that were included as DEGs from the GEO microarrays and TCGA, and the predicted target genes, were filtered further to collect the more specific target genes of miR-1. Finally, the validated target genes reported in the published literature were included in the genes for further analysis.

### Bioinformatics analysis

To uncover the potential crucial signal pathways and target genes of miR-1 in PCa, Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using DAVID 6.8 ([david-d.ncifcrf.gov/](david-d.ncifcrf.gov/)). P\<0.05 was considered to indicate a statistically significant difference. The false discovery rate was adopted to reflect the rate of type I errors in multiple comparisons. A protein-protein interaction (PPI) network was plotted using the plugin stringAPP 1.10 in Cytoscape 3.50 (<http://www.cytoscape.org/>) ([@b24-mmr-18-06-5630]), which has the ability to import the network from the STRING ([string-db.org](string-db.org)) database. Connection degrees \>3 among the nodes were used to select the hub genes.

### Validation of the hub genes

GEPIA (gepia.cancer-pku.cn), a newly developed interactive web server, was designed to analyze the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects using a standard processing pipeline ([@b25-mmr-18-06-5630]). Thus, GEPIA was used to validate the expression of the hub genes that were selected in the PPI. As miR-1 exerts it functions by specifically binding to its target genes, a Spearman\'s correlation analysis was conducted to validate the correlation between miR-1 and hub genes. The expression data of miR-1 and hub genes was downloaded from TCGA database. The expression data of miR-1 in TCGA included miR-1-1 and miR-1-2; therefore, the average expression of miR-1-1 and miR-1-2 was calculated to represent the expression of miR-1. The expression data of miR-1 and hub genes were normalized with log2 (x+1).

### Clinical value of miR-1 and hub genes in PCa

The data of miR-1, hub genes and clinical phenotype of PCa were obtained from TCGA database. The information of age, cancer status, residual tumor, Tumor, Node, Metastasis stage, survival time, final status, PSA level, hormone therapy and drug response were collected. The expression of miR-1, hub genes and PSA value were normalized with log~2~ (x+1). The expression difference analysis of miR-1, phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase (PAICS), cadherin 1 (CDH1), SRC proto-oncogene, non-receptor tyrosine kinase (SRC), twist family bHLH transcription factor 1 (TWIST1), ZW10 interacting kinetochore protein (ZW10), ZWINT, PCNA clamp associated factor (KIAA0101) and androgen receptor (AR) among AR-dependent, castrate-resistant (AR-independent) PCa and normal tissues were performed. The correlation among miR-1, upregulated hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) and PSA was investigated. The association between miR-1, upregulated hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) and clinicopathological parameters was investigated using SPSS 23.0 (IBM Corp., Armonk, NY, USA).

### Statistical analysis

The standard mean deviation (SMD) was used to evaluate the miR-1 expression differences between PCa and adjacent normal tissues via continuous variable meta-analysis in Stata 14.0 (StataCorp LLC, College Station, TX, USA). The fixed effects model was adopted to analyze the SMD if there was no heterogeneity among the included studies (I^2^\>50; P\<0.05). Otherwise, the random effects model was used. Begg and Deeks funnel plots were applied to test the publication bias of the included studies. Additionally, a sensitivity analysis was performed to demonstrate the influence of individual studies on the whole dataset. Summary receiver operating characteristic (SROC) curves, Fagan plots and forest plots of sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, diagnostic scores, in addition to odds ratios depicted through Stata 14.0 (StataCorp LLC), were performed to comprehensively evaluate the diagnostic value of miR-1 in PCa. Furthermore, bivariate boxplots and likelihood matrices were plotted to illustrate the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio in a plane coordinate system. SPSS 23.0 (IBM Corp.) and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA) were used for the clinicopathological parameter analysis and to display the results, respectively. Spearman\'s correlation analysis was used to analyze the correlation among miR-1, hub genes and PSA level. Student\'s t test was applied for comparison of two groups and the log-rank test was used for the survival analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression level of miR-1 in PCa

For all the included studies, the combined SMD was −0.31 \[95% confidence interval (CI), −0.60 to 0.22\] based on the random effects model (I2=87.8%; [Fig. 1](#f1-mmr-18-06-5630){ref-type="fig"}). Publication bias was not observed in the funnel plots, as it was basically symmetrical ([Fig. 2](#f2-mmr-18-06-5630){ref-type="fig"}). Significant heterogeneity was observed in the forest plot. As a result, a sensitivity analysis was performed, and it was considered that GSE54516 may cause heterogeneity ([Fig. 3](#f3-mmr-18-06-5630){ref-type="fig"}). Following removal of GSE54516, the combined SMD was −0.42 (95% CI, −0.52 to −0.32) with an I2=80.4%, which indicated downregulation ([Fig. 4](#f4-mmr-18-06-5630){ref-type="fig"}).

### Diagnostic value of miR-1 in PCa

An SROC curve was used to evaluate the pooled diagnostic value of miR-1 in the included studies. The SROC curve demonstrated that the pooled area under the curve (AUC) was 0.73 (95% CI, 0.69 to 0.77; [Fig. 5](#f5-mmr-18-06-5630){ref-type="fig"}), which suggested a moderate diagnostic efficacy of miR-1 in PCa. The combined sensitivity and specificity were 0.77 (95% CI, 0.62 to 0.88) and 0.57 (95% CI, 0.41 to 0.72), respectively ([Fig. 6](#f6-mmr-18-06-5630){ref-type="fig"}). The positive diagnostic likelihood ratio (DLR) and negative DLR were 1.82 (95% CI, 1.36 to 2.43) and 0.40 (95% CI, 0.26 to 0.60), respectively ([Fig. 7](#f7-mmr-18-06-5630){ref-type="fig"}). The diagnostic score and odds ratios were also calculated and were 1.53 (95% CI, 0.97 to 2.08) and 4.60 (95% CI, 2.63 to 8.04), respectively ([Fig. 8](#f8-mmr-18-06-5630){ref-type="fig"}). A Fagan plot was used to demonstrate how much the result on the diagnostic test alters the probability that a patient has PCa. The positive and negative posterior probabilities were 31 and 9%, respectively, and the pre-test probability was 20%. ([Fig. 9](#f9-mmr-18-06-5630){ref-type="fig"}). Deek\'s funnel plot was created to check for the potential publication bias of included studies. As demonstrated in [Fig. 10](#f10-mmr-18-06-5630){ref-type="fig"}, the Deek\'s funnel plot obtained a P-value of 0.85, which suggested there was no publication bias in the diagnostic meta-analysis. A bivariate boxplot was additionally constructed to assess distributional properties of sensitivity vs. specificity and to identify potential outliers ([Fig. 11](#f11-mmr-18-06-5630){ref-type="fig"}). An index test was used to display informativeness of measured test, which displayed the distribution of positive and negative likelihood ratio in the diagnostic meta-analysis ([Fig. 12](#f12-mmr-18-06-5630){ref-type="fig"}). Collectively, no publication bias existed in the present study and downregulated miR-1 demonstrated moderate diagnostic accuracy in PCa.

### Collection of possible target genes

In the GEO microarray datasets, GSE26032 and GSE31620, which included transfection of pre-miR oligos in prostate carcinoma cell lines to overexpress, were finally included. The expression data of the genes was extracted and the log~2~FC was calculated. With the standard log~2~FC\<0, the downregulated genes were collected. A total of 1,239 genes were finally gathered following intersecting the downregulated genes in GSE26032 and GSE31620, which contained two and three paired samples, respectively. For TCGA DEGs, the log~2~FC\>1 was restricted and 684 genes were obtained. Furthermore, 10,025 predicted target genes were gathered using the 12 online prediction tools. To improve the specificity of the putative target genes of miR-1, the GEO downregulated genes were intersected, TCGA DEGs, in addition to the predicted genes, and 45 putative significant genes were finally obtained for further bioinformatics analysis ([Table I](#tI-mmr-18-06-5630){ref-type="table"}).

### Bioinformatics analysis

A total of 45 promising overlapping target genes were collected for the bioinformatics analysis ([Table II](#tII-mmr-18-06-5630){ref-type="table"}; [Fig. 13](#f13-mmr-18-06-5630){ref-type="fig"}). The GO annotation elucidated that the promising target genes of miR-1 were closely associated with 'the response to the drug', 'adherens junction organization' and 'androgen receptor signaling pathway' in the 'biological process' (BP) domain. For the 'cellular component' (CC) domain, the promising miR-1 targets were mostly associated with the 'perinuclear region of cytoplasm', 'extracellular exosome' and 'membrane'. In the 'molecular function' (MF) domain, the putative miR-1 targets were mostly enriched in the 'androgen receptor activity', the 'transcription factor binding' and 'cadherin binding involved in cell-cell adhesion'. In addition, the KEGG pathway analysis demonstrated that the 'protein processing pathway in the endoplasmic reticulum' was the most significant. Using the PPI network, the construction of seven hub genes (PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR) were identified to act as the potential key targets of miR-1 in PCa ([Fig. 14](#f14-mmr-18-06-5630){ref-type="fig"}).

### Validation of the hub genes

The expression of the seven hub genes (PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR) was analyzed in the PCa and adjacent normal samples from TCGA and GTEx. A total of 492 PCa and 152 normal tissue samples were enrolled in the expression validation. Among the seven hub genes, it was observed that five of them (PAICS, CDH1, KIAA0101, TWIST1, and ZWINT) were significantly upregulated in PCa samples ([Fig. 15A-E](#f15-mmr-18-06-5630){ref-type="fig"}), which gave them more potential to be the key target genes of miR-1 in PCa. The other two hub genes (SRC and AR) did not demonstrate statistical significance between PCa and normal tissues based on the current data ([Fig. 15F and G](#f15-mmr-18-06-5630){ref-type="fig"}). Spearman\'s correlation analysis between miR-1 and the five up-regulated hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) was performed ([Fig. 16](#f16-mmr-18-06-5630){ref-type="fig"}). A significant negative correlation was identified between miR-1 and PAICS, ZWINT, in addition to KIAA0101 (P\<0.001; [Fig. 16A-C](#f16-mmr-18-06-5630){ref-type="fig"}), which supported their specific binding. Regarding CDH1 and TWIST1, a trend of negative correlation with miR-1 was observed ([Fig. 16D and E](#f16-mmr-18-06-5630){ref-type="fig"}). However, no statistical significance was revealed.

### Clinical significance of miR-1 and hub genes in PCa

The alterations of miR-1/hub genes among 31 AR-dependent, 9 castrate-resistant PCa and 52 normal tissues were compared. For AR-dependent and castrate-resistant PCa, miR-1 was significantly downregulated; whereas, PAICS, TWIST1, ZWINT and KIAA0101 were significantly upregulated compared with normal tissues (P\<0.001; [Fig. 17A and B](#f17-mmr-18-06-5630){ref-type="fig"}). Regarding CDH1, SRC and AR, the expression of SRC and AR only demonstrated significant increase in AR-dependent PCa not castrate-resistant PCa, while CDH1 did not reveal any alterations in AR-dependent and castrate-resistant PCa compared with normal tissues ([Fig. 17A and B](#f17-mmr-18-06-5630){ref-type="fig"}). However, for comparison between AR-dependent and castrate-resistant PCa, no statistically significant expression difference of miR-1 or hub genes was observed ([Fig. 17C](#f17-mmr-18-06-5630){ref-type="fig"}). Further studies with larger samples are required to elucidate the alterations of miR-1 or hub genes among AR-dependent, castrate-resistant PCa and normal tissues. The correlation among miR-1, upregulated hub genes and PSA level was investigated. In [Fig. 18](#f18-mmr-18-06-5630){ref-type="fig"}, the expression of miR-1 was negatively correlated with PSA level. Regarding the five upregulated hub genes, statistically significant negative correlation among PAICS, ZWINT, KIAA0101 and PSA level was identified. However, for CDH1 and TWIST1, no significantly negative correlation with PSA level was revealed. A total of 491 PCa samples were included for the clinicopathological features analysis. As demonstrated in [Table III](#tIII-mmr-18-06-5630){ref-type="table"}, the association among miR-1, upregulated hub genes and clinicopathological parameters is presented. In summary, miR-1 was significantly associated with cancer status, distant metastasis and lymph node metastasis and CDH1 was identified to be associated with age, cancer status and residual tumor. TWIST1 was only associated with pathological T stage. Furthermore, ZWINT was associated with cancer status, residual tumor, lymph node metastasis and pathological T stage; whereas, KIAA0101 was associated with age, cancer status, residual tumor, lymph node metastasis and pathological T stage. However, regarding PAICS, no statistically significant association with clinicopathological features was identified, and survival analysis of miR-1 and hub genes did not demonstrate statistical significance (data not shown).

Discussion
==========

PCa is the cancer type that results in the highest worldwide morbidity in the male population ([@b1-mmr-18-06-5630]). Searching for novel diagnostic biomarkers and examining the molecular mechanisms in PCa are of great importance for its clinical diagnosis and treatment. The present study aimed to evaluate the diagnostic value of miR-1 and identify the key target genes and signaling pathways in PCa.

Using comprehensive meta-analysis of expression data from the GEO, ArrayExpress, TCGA and published literature, it was identified that the expression of miR-1 was significantly downregulated in PCa compared with the adjacent normal tissues. It was demonstrated that miR-1 has a moderate diagnostic value in PCa (AUC, 0.73; sensitivity, 0.77; specificity, 0.57; odds ratio, 4.60). To the best of our knowledge, there is only one study, conducted by Pashaei *et al* ([@b26-mmr-18-06-5630]), which has identified downregulated miR-1 in recurrent PCa using a meta-analysis. However, there were only six GEO datasets included in the meta-analysis ([@b26-mmr-18-06-5630]). A larger sample may improve the integration and conviction of the study. In the present study, 27 GEO datasets, two published studies, one ArrayExpress microarray and two sets of TCGA data were analyzed.

Based on the online prediction databases, the potential target genes of miR-1 were collected to further examine the key enriched metabolic pathways in PCa. Subsequently, GO analysis revealed the enriched pathways in three categories. In 'BP', the 'response to drug', 'adherens junction organization', and 'androgen receptor signaling' pathways were the top three pathways. In 'CC', the top three items were the 'perinuclear region of the cytoplasm', the 'extracellular exosome', and the 'membrane'. In the 'MF', the target genes were primarily enriched in 'androgen receptor activity', 'transcription factor binding' and 'cadherin binding in cell-cell adhesion'. Furthermore, KEGG analysis identified a significant pathway, namely 'protein processing in the endoplasmic reticulum'. Among the above pathways discovered, it was identified that the 'androgen receptor signaling pathway', 'androgen receptor activity', 'transcription factor binding' and 'protein processing in the endoplasmic reticulum' have been previously reported. The 'androgen receptor signaling pathway' has been implicated in the therapeutic strategies of PCa ([@b27-mmr-18-06-5630]--[@b29-mmr-18-06-5630]). Regarding the 'androgen receptor activity', Ylitalo *et al* ([@b30-mmr-18-06-5630]) documented that it was involved in castrate-resistant PCa bone metastases. The regulation of androgen receptor activity was additionally discovered to be associated with therapy resistance and disease progression in PCa ([@b31-mmr-18-06-5630]--[@b33-mmr-18-06-5630]). Furthermore, transcription factor binding sites were additionally identified to be a crucial reaction domain in PCa, which may aid the explanation of the underlying regulatory mechanism ([@b34-mmr-18-06-5630],[@b35-mmr-18-06-5630]). Regarding KEGG pathway analysis, Kojima *et al* ([@b36-mmr-18-06-5630]) additionally revealed that 'protein processing in the endoplasmic reticulum' was a significant miR-143/145 regulated signal pathway in PCa, which may provide novel insights into the potential mechanism of PCa oncogenesis and metastasis. In summary, the enriched pathways, namely, the 'androgen receptor signaling pathway', 'androgen receptor activity', 'transcription factor binding', and 'protein processing in the endoplasmic reticulum', possess great potential to be involved the regulatory mechanisms of miR-1 in PCa. For the other pathways that have not been reported in PCa, further examination of their role in the regulatory mechanisms of miR-1 in PCa is worth pursuing.

Using the PPI network, seven hub genes (PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR) that may be the key target genes of miR-1 in PCa were identified. As miR-1 was downregulated in PCa, according to the meta-analysis, it was hypothesized that its target genes are upregulated accordingly. Thus, the expression of five hub genes was validated based on TCGA and GTEx data. It was identified that the five hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) were significantly upregulated in PCa. Since miR-1 was able to specifically bind to its targets, it was hypothesized that there is a correlation between miR-1 and its targets. As expected, there was significant negative correlation between miR-1 expression, and PAICS, ZWINT and KIAA0101 expression. Regarding CDH1 and TWIST1, a there was no significant correlation with miR-1. AR-dependent and castrate-resistant PCa may have different miRNA/mRNA expression profiles. Therefore, the expression of miR-1 and hub genes among AR-dependent, castrate-resistant PCa and normal tissues was investigated. In summary, it was identified that there was a trend that miR-1 was downregulated, while hub genes were upregulated in AR-dependent and castrate-resistant PCa compared with normal tissues. However, the expression difference of miR-1 and hub genes between AR-dependent and castrate-resistant PCa remains unclear. Studies with a larger sample size are required to elucidate the expression profiling alterations of miR-1/hub genes in AR-dependent and castrate-resistant PCa. Considering that PSA level was a useful specific marker in the clinical diagnosis of PCa, the correlation between miR-1/hub genes and PSA level was investigated. Notably, it was identified that miR-1 was negatively correlated with PSA level, while hub genes, PAICS, ZWINT and KIAA0101, were positively correlated with PSA level. Furthermore, it was identified that miR-1 and its hub genes were significantly associated with specific clinical phenotypes including age, tumor status, residual tumor, lymph node metastasis and pathological T stage. These results may pose a perspective for the clinical application of miR-1 and its hub genes. Combining PSA with miR-1/hub genes may be useful for the clinical diagnosis of PCa, and the involved molecular mechanism of miR-1 and its hub genes may shed light on novel therapies for patients with PCa. Consequently, the five upregulated genes, PAICS, CDH1, TWIST1, ZWINT and KIAA0101 were focused on for a more detailed discussion.

PAICS encodes a bifunctional enzyme. The octameric structure of the bifunctional enzyme PAICS in purine biosynthesis may contribute to PAICS-specific inhibitor design, which may be used in cancer chemotherapy ([@b37-mmr-18-06-5630]). PAICS has been reported as a therapeutic target in breast cancer ([@b38-mmr-18-06-5630]). Furthermore, increased PAICS was additionally identified to be associated with poor prognosis in lung cancer, which made it a promising prognostic biomarker ([@b39-mmr-18-06-5630]). Cifola *et al* ([@b40-mmr-18-06-5630]) first identified that PAICS was a mutated gene in melanoma. In the study conducted by Chakravarthi *et al* ([@b41-mmr-18-06-5630]), the role of PAICS in the proliferation and invasion of PCa cell was evaluated, implying that PAICS was a therapeutic target. Collectively, PAICS may be a promising target in PCa. However, its association with miR-1 still requires experimental validation.

CDH1, additionally termed uvomorulin and CDHE, encodes a classical cadherin of the cadherin superfamily. Loss of or reduced expression of CDH1 is thought to contribute to more invasive tumors ([@b42-mmr-18-06-5630]). A previous study discovered that CDH1 polymorphisms may be a prognostic indicator in non-metastatic laryngeal cancer ([@b43-mmr-18-06-5630]). Jiao *et al* ([@b44-mmr-18-06-5630]) identified that aberrant CDH1 was able to predict a poor prognosis for patients with pancreatic cancer. In addition, CDH1 was additionally identified to be associated with the risk of lung cancer ([@b45-mmr-18-06-5630]), breast cancer ([@b46-mmr-18-06-5630]), and gastric cancer ([@b47-mmr-18-06-5630]), and may be a potential drug target. In PCa, there was additionally a meta-analysis that evaluated CDH1-60 C/A polymorphism as a risk factor in the development of PCa ([@b48-mmr-18-06-5630]). In summary, CDH1 was a promising key target in PCa; however, it requires further experimental evaluation.

TWIST1 was reported to be implicated in cell lineage determination and differentiation. TWIST1 has been revealed to serve as an effective target for cancer metastasis and chemoresistance ([@b49-mmr-18-06-5630]). In pancreatic cancer, TWIST1 was identified as a therapeutic target and prognostic marker for tumor metastasis ([@b50-mmr-18-06-5630]). TWIST1 was additionally a target in lung cancer, which was correlated with the inhibition of proliferation, epithelial-mesenchymal transition and metastasis ([@b51-mmr-18-06-5630]). Furthermore, overexpression of TWIST1 was additionally identified to determine lung cancer chemoresistance and prognosis ([@b52-mmr-18-06-5630]). TWIST1 was additionally documented to be associated with the invasion and metastasis of gastric cancer ([@b53-mmr-18-06-5630],[@b54-mmr-18-06-5630]), and was a potential prognostic marker in colorectal cancer ([@b55-mmr-18-06-5630]--[@b57-mmr-18-06-5630]). Regarding PCa, numerous studies have reported that TWIST1 was involved in progression, including cancer invasion, migration and migration ([@b58-mmr-18-06-5630]--[@b63-mmr-18-06-5630]). As for the association between miR-1 and TWIST1, Chang *et al* ([@b19-mmr-18-06-5630]) discovered that epidermal growth factor receptor translocation promotes the bone metastasis of PCa by downregulating miR-1, which directly increases the expression of TWIST1. Given the above information, TWIST1 may be considered a key target of miR-1 in PCa. This finding requires further experimental research to validate it.

ZWINT encodes a protein that is involved in kinetochore function. Xu *et al* ([@b64-mmr-18-06-5630]) identified that ZWINT was increased in ovarian cancer and correlated with worse overall survival in patients with ovarian cancer. In bladder cancer, Ho *et al* ([@b65-mmr-18-06-5630]) observed that ZWINT was associated with a cell proliferation marker. ZWINT was additionally identified to be significantly correlated with the clinical outcome of chronic lymphocytic leukemia ([@b66-mmr-18-06-5630]). The association between ZWINT and PCa has not been reported in previously published literature. Further evidence is required to further elucidate the function of ZWINT in PCa.

KIAA0101 has been widely reported in the progression of various cancer types. For example, in hepatocellular carcinoma, overexpressed KIAA0101 was significantly associated with distant metastasis, advanced stage, early tumor recurrence and poor prognosis, which made it a potential therapeutic target ([@b67-mmr-18-06-5630]--[@b69-mmr-18-06-5630]). In gastric cancer, KIAA0101 was identified to be involved in the proliferation and invasion of PCa cells ([@b70-mmr-18-06-5630],[@b71-mmr-18-06-5630]). In addition, overexpression of KIAA0101 was indicated to predict poor survival in lung cancer ([@b72-mmr-18-06-5630]), esophageal cancer ([@b73-mmr-18-06-5630]) and renal cancer ([@b74-mmr-18-06-5630]). As for its role in PCa, to the best of our knowledge, no study at present has elucidated the association between KIAA0101 and PCa. Therefore, further studies are required to determine the precise role of KIAA0101 in PCa.

Collectively, it was identified that miR-1 was downregulated in PCa and was negatively correlated with PSA level. miR-1 was additionally associated with the tumor status, metastasis and lymph node metastasis of PCa. A total of seven hub genes, PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR, were identified. Five of them (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) were significantly upregulated in PCa and were negatively correlated with miR-1, which made them potential key target genes of downregulated miR-1 in PCa. The hub genes were associated with certain clinical features, including age, tumor status, residual tumor, lymph node metastasis, pathological T stage and PSA level. Using a review of published studies, further evidence was provided to support PAICS, CDH1 and TWIST1 as potential target genes of miR-1 in PCa. For ZWINT and KIAA0101, there is a lack of sufficient studies to demonstrate their role in PCa, and as such, they require further exploration. All the analyses in the present study were based on online database sources at the bioinformatics level. Therefore, further experimental studies are required to validate these genes. Nevertheless, the results obtained in the present study may aid the clinical diagnosis of PCa and provide insight into the molecular mechanisms of PCa.
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![Forest plot of the included data evaluating the expression difference between prostate cancer and normal tissues. Pooled SMD was calculated to present expression difference of miR-1. Random effect model was adopted. SMD, standard mean deviation; CI, confidence intervals; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.](MMR-18-06-5630-g00){#f1-mmr-18-06-5630}

![Funnel plot evaluating the publication bias. Each green node represents a separate study. Vertical line represents pooled SMD, while dotted lines represent confident interval. SMD, standard mean deviation; se, standard error.](MMR-18-06-5630-g01){#f2-mmr-18-06-5630}

![Sensitivity analysis screening the studies that might cause bias. Each study was omitted in turn to seek the source of heterogeneity. CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.](MMR-18-06-5630-g02){#f3-mmr-18-06-5630}

![Forest plot evaluating the miR-1 expression difference between prostate cancer and normal tissues after omitting the studies contributing to bias. Pooled SMD was calculated to present expression difference of miR-1. Fixed effect model was adopted. miR, microRNA; SMD, standard mean deviation; CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.](MMR-18-06-5630-g03){#f4-mmr-18-06-5630}

![SROC curve evaluating the diagnostic value of miR-1 in prostate cancer. Each plot with Arabic numeral inside represents a separate study. Red diamond represents summary operating point. SROC, summary receiver operating characteristic; AUC, area under the curve; SENS, sensitivity; SPEC, specificity.](MMR-18-06-5630-g04){#f5-mmr-18-06-5630}

![Sensitivity and Specificity Forest plots. Vertical dotted lines represent combined sensitivity and specificity. CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.](MMR-18-06-5630-g05){#f6-mmr-18-06-5630}

![Positive likelihood ratio and negative likelihood ratio forest plots. Vertical dotted lines represent combined positive likelihood and negative likelihood. DLR, diagnostic likelihood ratio; CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.](MMR-18-06-5630-g06){#f7-mmr-18-06-5630}

![Diagnostic score and odds ratio forest plots. Vertical dotted lines represent diagnostic score and odd ratio. CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.](MMR-18-06-5630-g07){#f8-mmr-18-06-5630}

![Fagan plot presenting the relationship of prior probability, the likelihood ratio and posterior test probability. The positive and negative likelihood ratio was 2 and 0.4, respectively. LR, likelihood ratio; Prob, probability.](MMR-18-06-5630-g08){#f9-mmr-18-06-5630}

![Deek\'s funnel plot evaluating the publication bias of the included studies in the diagnostic value assessment. P\>0.05 was used to determine no publication bias in the investigation. ESS, effective sample size.](MMR-18-06-5630-g09){#f10-mmr-18-06-5630}

![Bivariate boxplot evaluating the sensitivity and specificity in a plane coordinate system. Logit transforms of sensitivity and specificity was used to assess distributional properties of sensitivity vs. specificity and to identify possible outliers. The mean logit sensitivity and specificity with their standard errors and 95% confidence intervals is presented in the gray area. SENS, sensitivity; SPECS, specificity.](MMR-18-06-5630-g10){#f11-mmr-18-06-5630}

![Likelihood matrix evaluating the positive likelihood ratio and negative likelihood ratio in a plane coordinate system. Plot was divided into quadrants based on strength-of-evidence thresholds. Informativeness of measured test was used to determine the distribution of positive and negative likelihood ratio in our diagnostic meta-analysis. LUQ, left upper quadrant; RUQ, right upper quadrant; LLQ, left lower quadrant; RLQ, right lower quadrant; LRP, positive likelihood ratio; LRN, negative likelihood ratio.](MMR-18-06-5630-g11){#f12-mmr-18-06-5630}

![Significant GO annotation and KEGG pathways of the overlapping genes. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-18-06-5630-g12){#f13-mmr-18-06-5630}

![Protein-protein interactive network of the overlapping genes. Each point represents a protein. Degree sorted circle layout was adopted.](MMR-18-06-5630-g13){#f14-mmr-18-06-5630}

![Box plots for the expression of hub genes in prostate cancer and normal tissues. Box plots for the expression of (A) PAICS, (B) CDH1, (C) KIAA0101, (D) TWIST1, (E) ZWINT, (F) SRC and (G) AR. Mean and standard deviation value were calculated for the comparison. \*P\<0.05. PRAD, prostate adenocarcinoma; PAICS, phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccino carboxamide synthase; CDH1, cadherin 1; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor; AR, androgen receptor; T, tumor; N, normal.](MMR-18-06-5630-g14){#f15-mmr-18-06-5630}

![Correlation between miR-1 and its upregulated hub genes. Correlation between miR-1 and (A) PAICS, (B) ZWINT, (C) KIAA0101, (D) CDH1 and (E) TWIST1. Yellow area represents 95% confidence interval. miR, microRNA; PAICS, phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase; CDH1, cadherin 1; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor.](MMR-18-06-5630-g15){#f16-mmr-18-06-5630}

![Expression of miR-1 and hub genes among AR-dependent, castrate-resistant PCa and normal tissues. Comparison of miR-1 and hub genes in (A) AR-dependent PCa and normal tissues; (B) castrate-resistant PCa and normal tissues; and (C) AR-dependent PCa and castrate-resistant PCa. Mean and standard deviation value were calculated for the comparison. miR, microRNA; AR, androgen receptor; PCa, prostate cancer; PAICS, phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccino carboxamide synthase; CDH1, cadherin 1; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor.](MMR-18-06-5630-g16){#f17-mmr-18-06-5630}

![Correlation between miR-1 or hub genes and PSA level. Correlation between PSA level and (A) miR-1, (B) PAICS, (C) CHD1, (D) TWIST1, (E) ZWINT and (F) KIAA0101 Yellow area represents 95% confidence interval. miR, microRNA; PSA, prostate-specific antigen; PAICS, phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase; CDH1, cadherin 1; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor.](MMR-18-06-5630-g17){#f18-mmr-18-06-5630}

###### 

54 putative potential targets of microRNA-1.

  Gene symbol   Official name
  ------------- --------------------------------------------------------------------------------------------------------
  SEL1L3        SEL1L family member 3
  PPM1H         Protein phosphatase, Mg2+/Mn2+ dependent 1H
  LMNB1         Lamin B1
  NKX3-1        NK3 homeobox 1
  SLC4A4        Solute carrier family 4 member 4
  AP1S1         Adaptor related protein complex 1 subunit sigma 1
  PPIB          Peptidylprolyl isomerase B
  PSAT1         Phosphoserine aminotransferase 1
  PABPC1        Poly(A) binding protein cytoplasmic 1
  BCAM          Basal cell adhesion molecule (Lutheran blood group)
  AGA           Aspartylglucosaminidase
  TMEM97        Transmembrane protein 97
  SSR1          Signal sequence receptor subunit 1
  GALNT1        Polypeptide N-acetylgalacto-saminyltransferase 1
  SEC23B        Sec23 homolog B, coat complex II component
  GOLM1         Golgi membrane protein 1
  DSG2          Desmoglein 2
  APLP2         Amyloid β (A4) precursor-like protein 2
  GCNT1         Glucosaminyl (N-acetyl) transferase 1, core 2
  EPB41L4B      Erythrocyte membrane protein band 4.1 like 4B
  CLCN3         Chloride voltage-gated channel 3
  PDIA6         Protein disulfide isomerase family A member 6
  SLC27A2       Solute carrier family 27 member 2
  MYO6          Myosin VI
  DSC2          Desmocollin 2
  ABCC4         ATP binding cassette subfamily C member 4
  SLC45A2       Solute carrier family 45 member 2
  NUP210        Nucleoporin 210
  PAICS         Phosphoribosylaminoimidazole carboxylase and phosphoribo-sylaminoimidazolesuccino-carboxamide synthase
  CENPF         Centromere protein F
  ACSL3         Acyl-CoA synthetase long chain family member 3
  PPP3CA        Protein phosphatase 3 catalytic subunit α
  ABHD2         Abhydrolase domain containing 2
  NCAPD3        Non-SMC condensin II complex subunit D3
  SEL1L3        SEL1L family member 3
  MAP7          Microtubule associated protein 7
  ZWINT         ZW10 interacting kinetochore protein
  NAAA          N-acylethanolamine acid amidase
  TUSC3         Tumor suppressor candidate 3
  PCLAF         PCNA clamp associated factor
  ETO2          Neuropilin and tolloid like 2
  TPD52         Tumor protein D52
  CDH1          Cadherin 1
  CADM1         Cell adhesion molecule 1
  EIF2AK1       Eukaryotic translation initiation factor 2 α kinase 1
  PMEPA1        Prostate transmembrane protein, androgen induced 1
  PNP           Purine nucleoside phosphorylase
  PTMA          Prothymosin α
  AR            Androgen receptor
  SRC           SRC proto-oncogene, non-receptor tyrosine kinase
  TWIST1        Twist family bHLH transcription factor 1
  Slug          Snail family transcriptional repressor 2
  KLF4          Kruppel like factor 4
  XPO6          Exportin 6
  TWF1          Twinfilin actin binding protein 1

###### 

Significant GO and KEGG pathways of the overlapping genes.

  Category           Term                                                                                                      Count   P-value    FDR
  ------------------ --------------------------------------------------------------------------------------------------------- ------- ---------- ----------
  GOTERM_BP_DIRECT   GO:0042493\~response to drug                                                                                6     0.00187    2.677129
  GOTERM_BP_DIRECT   GO:0034332\~adherens junction organization                                                                  3     0.005205   7.287529
  GOTERM_BP_DIRECT   GO:0030521\~androgen receptor signaling pathway                                                             3     0.006361   8.837711
  GOTERM_BP_DIRECT   GO:0010628\~positive regulation of gene expression                                                          5     0.007078   9.786328
  GOTERM_BP_DIRECT   GO:0007156\~homophilic cell adhesion via plasma membrane adhesion molecules                                 4     0.010974   14.78529
  GOTERM_BP_DIRECT   GO:0086073\~bundle of His cell-Purkinje myocyte adhesion involved in cell communication                     2     0.017384   22.45141
  GOTERM_BP_DIRECT   GO:0044539\~long-chain fatty acid import                                                                    2     0.020252   25.66973
  GOTERM_BP_DIRECT   GO:0014067\~negative regulation of phosphatidylinositol 3-kinase signaling                                  2     0.028808   34.54625
  GOTERM_BP_DIRECT   GO:0006886\~intracellular protein transport                                                                 4     0.031444   37.07541
  GOTERM_BP_DIRECT   GO:0098911\~regulation of ventricular cardiac muscle cell action potential                                  2     0.031644   37.26326
  GOTERM_BP_DIRECT   GO:0071456\~cellular response to hypoxia                                                                    3     0.031963   37.56294
  GOTERM_BP_DIRECT   GO:2000679\~positive regulation of transcription regulatory region DNA binding                              2     0.042905   47.05066
  GOTERM_CC_DIRECT   GO:0048471\~perinuclear region of cytoplasm                                                               12      9.07E-07   0.001083
  GOTERM_CC_DIRECT   GO:0070062\~extracellular exosome                                                                         21      3.29E-05   0.039319
  GOTERM_CC_DIRECT   GO:0016020\~membrane                                                                                      17      0.000218   0.25958
  GOTERM_CC_DIRECT   GO:0005913\~cell-cell adherens junction                                                                     7     0.000272   0.324715
  GOTERM_CC_DIRECT   GO:0005789\~endoplasmic reticulum membrane                                                                  8     0.009743   11.03435
  GOTERM_CC_DIRECT   GO:0016323\~basolateral plasma membrane                                                                     4     0.013947   15.44149
  GOTERM_CC_DIRECT   GO:0032587\~ruffle membrane                                                                                 3     0.022114   23.43573
  GOTERM_CC_DIRECT   GO:0000139\~Golgi membrane                                                                                  6     0.024307   25.46094
  GOTERM_CC_DIRECT   GO:0031965\~nuclear membrane                                                                                4     0.02621    27.17933
  GOTERM_CC_DIRECT   GO:0005783\~endoplasmic reticulum                                                                           7     0.027342   28.18388
  GOTERM_CC_DIRECT   GO:0034663\~endoplasmic reticulum chaperone complex                                                         2     0.030365   30.80375
  GOTERM_CC_DIRECT   GO:0005794\~Golgi apparatus                                                                                 7     0.032588   32.67453
  GOTERM_CC_DIRECT   GO:0016021\~integral component of membrane                                                                22      0.032972   32.99373
  GOTERM_CC_DIRECT   GO:0005737\~cytoplasm                                                                                     22      0.037093   36.3252
  GOTERM_MF_DIRECT   GO:0004882\~androgen receptor activity                                                                      2     0.009037   12.08615
  GOTERM_MF_DIRECT   GO:0008134\~transcription factor binding                                                                    5     0.010545   12.91881
  GOTERM_MF_DIRECT   GO:0098641\~cadherin binding involved in cell-cell adhesion                                                 5     0.01132    16.85447
  GOTERM_MF_DIRECT   GO:0050839\~cell adhesion molecule binding                                                                  3     0.015076   19.38597
  GOTERM_MF_DIRECT   GO:0008022\~protein C-terminus binding                                                                      4     0.017579   19.79801
  GOTERM_MF_DIRECT   GO:0086083\~cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication     2     0.017993   23.42536
  GOTERM_MF_DIRECT   GO:0005102\~receptor binding                                                                                5     0.021727   25.48576
  GOTERM_MF_DIRECT   GO:0102391\~decanoate-CoA ligase activity                                                                   2     0.02392    26.92366
  GOTERM_MF_DIRECT   GO:0008013\~β-catenin binding                                                                               3     0.025484   38.00481
  GOTERM_MF_DIRECT   GO:0004467\~long-chain fatty acid-CoA ligase activity                                                       2     0.038584   57.75621
  KEGG_PATHWAY       hsa04141:Protein processing in endoplasmic reticulum                                                        5     0.004469   10.44355

GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Association between miR-1/hub genes and clinicopathological parameters in prostate cancer.

  A, miR-1                                                                            
  --------------------------------- ------- ---------------------------- ------------ -------------------------------------------------------
  Age (years)                                                            1.605        0.109
    \<60                            199     8.759±1.229                               
    ≥60                             292     8.569±1.332                               
  Tumor status                                                           −2.317       0.021^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    With tumor                      93      8.391±1.328                               
    Tumor-free                      310     8.746±1.286                               
  Residual tumor                                                         1.836        0.067
    No                              311     8.728±1.255                               
    Yes                             150     8.495±1.318                               
  Distant metastasis                                                     −4.455       0.000^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              451     4.617±2.286                               
    Yes                             2       8.677±1.283                               
  Lymph node metastasis                                                  2.764        0.006^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              342     8.713±1.251                               
    Yes                             77      8.281±1.172                               
  Pathological T                                                         1.869        0.062
    T1 + T2                         186     8.782±1.183                               
    T3 + T4                         298     8.561±1.316                               
                                                                                      
  **B, PAICS**                                                                        
                                                                                      
  **Clinicopathological feature**   **n**   **Expression (mean ± SD)**   **t-test**   **P-value**
                                                                                      
  Age (years)                                                            0.48         0.631
    \<60                            199     4.368±0.489                               
    ≥60                             292     4.347±0.488                               
  Tumor status                                                           1.156        0.249
    With tumor                      93      4.409±0.576                               
    Tumor-free                      310     4.340±0.473                               
  Residual tumor                                                         −0.153       0.878
    No                              311     4.358±0.488                               
    Yes                             150     4.365±0.493                               
  Distant metastasis                                                     1.788        0.075
    No                              451     4.350±0.486                               
    Yes                             2       4.966±0.697                               
  Lymph node metastasis                                                  0.213        0.832
    No                              342     4.356±0.509                               
    Yes                             77      4.343±0.406                               
  Pathological T                                                         −1.193       0.233
    T1 + T2                         186     4.323±0.485                               
    T3 + T4                         298     4.377±0.487                               
                                                                                      
  **C, CDH1**                                                                         
                                                                                      
  **Clinicopathological feature**   **n**   **Expression (mean ± SD)**   **t-test**   **P-value**
                                                                                      
  Age (years)                                                            2.4          0.017^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    \<60                            199     6.593±0.710                               
    ≥60                             292     6.431±0.754                               
  Tumor status                                                           −3.135       0.002^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    With tumor                      93      6.306±1.018                               
    Tumor-free                      310     6.586±0.658                               
  Residual tumor                                                         2.967        0.003^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              311     6.583±0.636                               
    Yes                             150     6.338±0.912                               
  Distant metastasis                                                     −1.192       0.234
    No                              451     6.490±0.723                               
    Yes                             2       5.880±0.697                               
  Lymph node metastasis                                                  1.185        0.237
    No                              342     6.521±0.681                               
    Yes                             77      6.409±1.003                               
  Pathological T                                                         1.631        0.104
    T1+T2                           186     6.567±0.646                               
    T3+T4                           298     6.454±0.793                               
                                                                                      
  **D, TWIST1**                                                                       
                                                                                      
  **Clinicopathological feature**   **n**   **Expression (mean ± SD)**   **t-test**   **P-value**
                                                                                      
  Age (years)                                                            −0.549       0.583
    \<60                            199     2.307±1.131                               
    ≥60                             292     2.363±1.107                               
  Tumor status                                                           1.274        0.203
    With tumor                      93      2.404±1.198                               
    Tumor-free                      310     2.240±1.056                               
  Residual tumor                                                         −1.636       0.103
    No                              311     2.271±1.067                               
    Yes                             150     2.454±1.241                               
  Distant metastasis                                                     1.444        0.150
    No                              451     2.329±1.110                               
    Yes                             2       3.463±0.032                               
  Lymph node metastasis                                                  −1.629       0.104
    No                              342     2.271±1.067                               
    Yes                             77      2.501±1.329                               
  Pathological T                                                         −2.244       0.025^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    T1+T2                           186     2.200±1.053                               
    T3+T4                           298     2.434±1.154                               
                                                                                      
  **E, ZWINT**                                                                        
                                                                                      
  **Clinicopathological feature**   **n**   **Expression (mean ± SD)**   **t-test**   **P-value**
                                                                                      
  Age (years)                                                            −1.482       0.139
    \<60                            199     2.279±0.693                               
    ≥60                             292     2.375±0.715                               
  Cancer status                                                          3.495        0.001^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    With tumor                      93      2.570±0.839                               
    Tumor-free                      310     2.241±0.645                               
  Residual tumor                                                         −3.458       0.001^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              311     2.255±0.641                               
    Yes                             150     2.505±0.764                               
  Distant metastasis                                                     0.629        0.643
    No                              451     2.339±0.693                               
    Yes                             2       3.629±2.902                               
  Lymph node metastasis                                                  −3.193       0.002^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              342     2.287±0.662                               
    Yes                             77      2.607±0.821                               
  Pathological T                                                         −4.94        0.000^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    T1+T2                           186     2.157±0.526                               
    T3+T4                           298     2.445±0.758                               
                                                                                      
  **F, KIAA0101**                                                                     
                                                                                      
  **Clinicopathological feature**   **n**   **Expression (mean ± SD)**   **t-test**   **P-value**
                                                                                      
  Age (years)                                                            −2.284       0.023^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    \<60                            199     1.067±0.506                               
    ≥60                             292     1.181±0.590                               
  Cancer status                                                          3.41         0.001^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    With tumor                      93      1.322±0.692                               
    Tumor-free                      310     1.059±0.495                               
  Residual tumor                                                         −3.188       0.002^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              311     1.063±0.498                               
    Yes                             150     1.249±0.624                               
  Distant metastasis                                                     0.958        0.514
    No                              451     1.135±0.553                               
    Yes                             2       2.353±1.799                               
  Lymph node metastasis                                                  −2.806       0.006^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    No                              342     1.118±0.532                               
    Yes                             77      1.347±0.671                               
  Pathological T                                                         −6.185       0.000^[a](#tfn2-mmr-18-06-5630){ref-type="table-fn"}^
    T1+T2                           186     0.960±0.405                               
    T3+T4                           298     1.243±0.599                               

Statistically significant. miRNA/miR, microRNA; SD, standard deviation; PAICS, phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase; CDH1, cadherin 1; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor.
